Bio-Rad Laboratories, Inc. (BIO) Stock Forecast
BIO analyst forecast
as of October 18, 2026- Analyst consensus
- Hold 3.00 / 5 from 3 analysts
- Price target
- $335.00 average of analyst targets
- Upside to target
- −5.3% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $2.61
- 52-week range
- $241.71 – $390.34
BIO analyst ratings
3 analystsNumber of analysts at each rating.
BIO price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
BIO earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $2.23 | $2.16 | $2.29 | $2.26 | −1.6% | 2 |
| Current fiscal year (2026) | $9.45 | $8.85 | $10.10 | $9.92 | −4.7% | 3 |
| Next fiscal year (2027) | $9.75 | $8.75 | $10.90 | $9.45 | +3.1% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
BIO revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $650.0M | $647.8M | $652.1M | −0.5% | 2 |
| Current fiscal year (2026) | $2.57B | $2.53B | $2.59B | −0.5% | 3 |
| Next fiscal year (2027) | $2.62B | $2.53B | $2.67B | +2.1% | 3 |
BIO EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
BIO revenue: reported and forecast
BIO EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $2.31 | $2.23 | $2.23 | $2.23 | $2.23 | −3.7% | 0 up · 3 down |
| Current fiscal year (2026) | $9.00 | $9.48 | $9.48 | $9.45 | $9.45 | +5.0% | 4 up · 0 down |
| Next fiscal year (2027) | $9.72 | $10.03 | $10.03 | $9.92 | $9.75 | +0.3% | 4 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
BIO earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; BIO beat in 9 of 12.
What analysts expect from BIO
3 analysts cover Bio-Rad Laboratories; their consensus rating is hold (3.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $335.00, 5.3% below the latest close of $353.70. Analysts expect earnings of $9.45 per share for 2026, −4.7% from a year earlier. For 2027 the average estimate is $9.75 per share on revenue of $2.6 billion. Bio-Rad Laboratories beat the EPS estimate in 9 of the last 12 quarters.
Related: BIO income statement, BIO key metrics, BIO chart. See the BIO stock overview for the latest quote and news.
BIO forecast FAQ
What is Bio-Rad Laboratories's price target?
The average analyst price target for Bio-Rad Laboratories is $335.00, 5.3% below the latest close of $353.70.
Is Bio-Rad Laboratories a buy, hold or sell?
Of 3 analysts covering Bio-Rad Laboratories, 0 rate it a strong buy, 1 a buy, 1 a hold, 1 a sell and 0 a strong sell, a consensus of hold. Ratings are opinions, not a recommendation from Quotelinks.
What is Bio-Rad Laboratories's EPS forecast?
Analysts forecast $9.45 per share for 2026 (range $8.85 to $10.10); for 2027 the estimate is $9.75.
What is Bio-Rad Laboratories's revenue forecast?
The average revenue estimate for 2026 is $2.6 billion, growth of −0.5%; for 2027 it is $2.6 billion.
When does Bio-Rad Laboratories report earnings?
Bio-Rad Laboratories is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes; the EPS estimate is $2.61.
Does Bio-Rad Laboratories usually beat earnings estimates?
Bio-Rad Laboratories reported EPS at or above the analyst estimate in 9 of the last 12 quarters.